Dr. Barry Garfinkle Joins PBS Biotech Scientific Advisory Board
Innovative Bioprocess Solutions
NEWS RELEASE, For Immediate Release
Former Merck Executive Dr. Barry Garfinkle Joins
PBS Biotech, Inc. Scientific Advisory Board
Biotech expert provides technical, regulatory and leadership to the fast growing bioreactor company. Will assist firm’s market intro and shape quality standards.
Camarillo, California, May 25, 2011–PBS Biotech, Inc., a developer of state of the art single-use bioreactors used in the fast growing biotechnology market, announced today Dr. Barry Garfinkle, former vice president of Biological Sciences and Strategy of Merck & Co., a global research-driven pharmaceutical company, has joined the firm’s Scientific Advisory Board which includes accomplished executives, business leaders, and scientists from the leading biopharmaceutical companies and academic institutes. PBS Biotech’s bioreactors help cut costs and accelerate time to market for worldwide makers of drugs, vaccines and biosimilars.
Dr. Garfinkle brings over 30 years experience in developing and manufacturing of vaccines, biological and sterile pharmaceuticals to PBS Biotech management team helping shape the company’s product design, market positioning and growth as the next generation single-use bioreactor.
“Barry has a broad range of expertise and success in facility design, validation and start up, regulatory affairs and business leadership that will provide significant value to our company as we introduce our single-use bioreactors to the market,” said Dr. Brian Lee, president and co-founder of PBS Biotech. “His knowledge of materials, regulatory issues and process of R&D to manufacturing as well as market dynamics are invaluable in helping us provide unequalled benefits to customers,” he said.
Before leading the Biological and Strategy team at Merck, Dr. Garfinkle was for nearly a decade Merck’s VP of Technology and Engineering overseeing all facility design, technical transfer from research, plant start up and technical support for all sterile and vaccine products at Merck. As VP of Merck’s Vaccine Policy he led global quality activities and served as head of Merck’s interaction with the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation & Research (CBER). Dr. Garfinkle has a strong background in regulatory and quality with FDA, CBER, EU and Australia troubleshooting of biological processes and productivity improvements.
“Dr. Lee and the PBS Biotech team have developed a product line of bioreactors with the potential to transform the industry’s adoption of single-use technology,” said Dr. Garfinkle. “These systems offer all the features and benefits customers are seeking to make their R&D to manufacturing operations more competitive, while driving out costs and improving overall efficiency,” he said, adding the units are well suited to help advance the development of biosimilars as well as new drugs and vaccines worldwide.
Dr. Garfinkle currently heads his own biopharma consulting firm Barry Garfinkle & Associates LLC, Philadelphia, PA. He earned a PhD in microbiology and virology from Penn State University and was a postdoctoral fellow at Roche Institute of Molecular Biology, Nutley, NJ.
About PBS Biotech
PBS Biotech, Inc. is a US corporation that manufactures fully scalable and easy to use single-use bioreactors for global biotechnology organizations. The company has patented innovative industrial designs and advanced software driven control systems that produce low shear, cell culture solutions improving operational flexibility and process efficiency, reducing operating costs and accelerating time to market for biotechnology customers. With headquarters in Camarillo, CA. the company is poised for rapid growth to support industry demand for single-use technologies.
Contact: James B. Schultz, VP – Sales & Marketing
+1 805-990-6177
PDF Version 
PBS Biotech® Exhibits Bioreactors at 22nd Annual ESACT conference in Vienna
Innovative Bioprocess Solutions
NEWS RELEASE, For Immediate Release
PBS Biotech® Exhibits Bioreactors at
22nd Annual ESACT conference in Vienna
Sees rapid growth for single-use bioreactors in lab to production applications
Camarillo, CA. May 13—PBS Biotech, Inc., a developer of state of the art bioreactors used in the fast growing biotechnology market, announced today its attendance at the 22nd Annual European Society for Animal Cell Technology (ESACT) Conference in Vienna, Austria, May 15-18. The ESACT conference is one of the largest cell culture conferences in the world, bringing together leading academia and industry scientists to advance cell-based technologies. PBS Biotech is located in booth #226 in the Wintergarten section of the Hofsburg Congress Center Exhibit Hall.
Dr. Brian Lee, co-founder and President; Mr. Daniel Giroux VP – R&D and Mr. James Schultz, VP – Sales & Marketing will be in attendance.
PBS Biotech will be representing its line of next generation single-use bioreactors for use in developing cell cultures for wide range of products including mAbs, proteins, vaccines, viruses, stem cells and personalized medicine. The company will display its PBS 3, PBS 15 and PBS 80 liter line of bioreactors used in batch, fed batch, perfusion and transient transfection applications.
The company projects rapid adoption of single-use bioreactors across all stages of the bioprocess as firms desire to embrace single-use technology in general and a biotech industry desiring to drive out costs in both R&D and production while increasing process flexibility, operational flexibility and accelerating time to market.
The PBS Biotech line of products are most advanced in the industry featuring ease of use, full scalability from lab to production, low shear from the novel Air-Wheel™ mixing mechanism and plug and play configurations.
PBS encourages attendees to stop by its booth to learn more about its products and how they can help cell culture scientists and process developers put the next generation of single-use bioreactors to use in their facilities.
About PBS Biotech
PBS Biotech, Inc. is a US corporation that manufactures fully scalable and easy to use single-use bioreactors for global biotechnology organizations. The company has patented innovative industrial designs and advanced software driven control systems that produce low shear, cell culture solutions improving operational flexibility and process efficiency, reducing operating costs and accelerating time to market for biotechnology customers. With headquarters in Camarillo, CA. the company is poised for rapid growth to support industry demand for single-use technologies.
Contact: James B. Schultz, VP – Sales & Marketing
+1 805-990-6177
PDF Version
PBS Biotech® Launches Single-Use Bioreactor for Development of New Vaccines and Biosimilars
Innovative Bioprocess Solutions
NEWS RELEASE, For Immediate Release
PBS Biotech® Launches Single-Use Bioreactor for Development of New Vaccines and Biosimilars
Benchtop size, easy-to-use, plug and play bioreactor using advanced Air-Wheel™ mixing technology reduces cost and time to market
Camarillo, California, May 11, 2011 – PBS Biotech, Inc., a developer of state of the art bioreactors to be used in the fast growing biotechnology market, announced today the launch of its innovative PBS 3 single-use bioreactor system. This novel bioreactor, designed by cell culture scientists and engineers, offers a more rapid and cost-effective development option for new biological therapeutics and vaccines as well as emerging biosimilar products.
The PBS 3 bioreactor with its patented Air-Wheel™ system employs a unique, low shear, pneumatic mixing mechanism, and has a 3-liter maximum working volume capacity. The unique feature of fast mixing with low shear stress and high oxygen transfer rates enables the cultivation of a wide range of animal, plant, and insect cells. This widens the potential for development of new monoclonal antibodies, therapeutic proteins, and vaccines as well as stem cells for personalized medicine. Launch of a complete line of larger, fully scalable bioreactors through commercial scale production size will follow over the next several months.
The PBS 3 is a fully integrated and pre-configured system with powerful process control capability in one-third the size and weight of competing systems. The benchtop unit can be installed by a single operator within minutes and securely monitored or controlled using the touch screen or remotely by computer or smart phone, including an iPhone® or iPad®, over a secured Internet or Ethernet connection. The disposable vessel is constructed of USP Class VI plastic to meet the cGMP regulatory requirements. Key product features include the Air-Wheel™ mixing mechanism, proprietary auto sampler system, and user-friendly graphical interface of the controller.
“Our PBS 3 liter system is the most advanced laboratory scale, single-use bioreactors in the industry and is the first in our family of products. The bioreactor’s innovative, ease-of-use, and compact design will provide unique benefits and value to customers who want to gain operational efficiency and flexibility for reduced developmental cost and time,” said Dr. Brian Lee, co-founder and president of PBS Biotech and former senior scientist at leading biopharmaceutical companies Amgen and Merck & Co.
“We are grateful for the support of our Advisory Board and the dedication of our product development team for their time and inspired ideas in creating the most advanced single-use bioreactors,” Dr. Lee added. PBS Biotech boasts pre-launch product trials and evaluations in numerous biotech and academic research organizations in North America, Europe, and Asia.
“The PBS 3 single-use bioreactor leads the way for scientists to upgrade existing equipment by adopting an entry level platform that is fully scalable from lab to production stages. We are particularly encouraged by the value proposition that we deliver for global biosimilar companies entering the market,” said James B. Schultz, VP of Sales and Marketing.
Biosimilars are generic biological drugs that are similar to the original branded products. The market for these generic products is expected to grow from $250 million today to over $4 billion by 2014 globally. Production of biosimilar products is extremely cost sensitive and requires significant operational efficiency and flexibility, which can be benefited from broader and immediate adoption of single-use bioreactors and related disposable products.
About PBS Biotech
PBS Biotech, Inc. is a U.S. corporation headquartered in Camarillo, California that manufactures fully scalable and easy-to-use single-use bioreactors for global biotechnology organizations. The company has developed innovative, efficient, and scalable bioreactors by combining a patented pneumatic mixing mechanism with an advanced, proprietary control system. This novel bioreactor solution offers improved operational efficiency and flexibility with reduced costs and ultimately shorter time to market for biotechnology customers. PBS Biotech is poised for rapid growth by supporting industry demand for single-use technologies.
Contact: James B. Schultz, VP – Sales & Marketing
+1 805-990-6177
PDF Version
PBS Biotech® and Refine Technology Provide Powerful Bioreactor, Perfusion Application for Biotech Users
Innovative Bioprocess Solutions
NEWS RELEASE, For Immediate Release
PBS Biotech® and Refine Technology Provide Powerful Bioreactor, Perfusion Application for Biotech Users
Benchtop size, plug and play bioreactor in tandem with the low profile
and high performance ATF™ System on display at ESACT in Vienna
Camarillo, California, May 11, 2011–PBS Biotech, Inc., a developer of state of the art single-use bioreactors used in the fast growing biotechnology market, announced today it has partnered with Refine Technology, Pine Brook, New Jersey to provide a powerful perfusion application providing high cell density solutions for biotech customers. The PBS 15 liter single-use bioreactor and the Refine Technology ATF4 system will be on display at the ESACT conference May 15-18 in Vienna.
PBS Biotech® and Refine Technology, two technology leaders in cell culture development, are the ideal pair for biotech lab to production perfusion applications. Boasting low profile, high performance and easy to use systems, the PBS Biotech 15L and PBS 80L single-use bioreactors can be configured with the Refine Technology ATF4 System and ATF6 System, respectively.
PBS bioreactors feature low shear mixing and high mass transfer rates from the patented Air Wheel™ mixing mechanism, making them a perfect complement to the Refine Technology ATF™ System which provides a reliable and efficient process of cell separation and supports cell growth to extreme concentrations. The ATF System allows increased volumetric productivity and reduced bioreactor size. Together the PBS Biotech single-use bioreactors and the Refine Technology perfusion systems are ideal for demanding R&D laboratory to clinical stage high-density cell culture applications including:
- Concentrated perfusion
- Concentrated fed batch
- Continuous culture
- Primary recovery/clarification
Key Benefits of the PBS/Refine Technology Solution:
- Significantly increased cell density
- Simpler cell separation
- Low profile, ease of use and high performance
- Reduced equipment costs
- Reduce vaccine and protein development and production costs
- Increase operational flexibility and process efficiency
About PBS Biotech
PBS Biotech, Inc. is a US corporation that manufactures fully scalable and easy to use single-use bioreactors for global biotechnology organizations. The company has patented innovative industrial designs and advanced software driven control systems that produce low shear, cell culture solutions improving operational flexibility and process efficiency, reducing operating costs and accelerating time to market for biotechnology customers. With headquarters in Camarillo, CA. the company is poised for rapid growth to support industry demand for single-use technologies.
About Refine Technology
Refine Technology was founded in 1999 with a vision to bring to the biopharmaceutical market cell separation systems that allow for increased productivity of cell derived biopharmaceuticals. Refine soon introduced its patented ATF System which is now being used in the development and manufacturing facilities of many biological and pharmaceutical companies.
PBS Biotech Contact: James B. Schultz, VP – Sales & Marketing
+1 805-990-6177
www.pbsbiotech.com
Refine Technology Contact: John Bonham-Carter, VP – Sales & Business Development
+1 (732) 993-3003 and EU +46 76 256 5114
www.refinetech.com
PDF Version
Randy Ray Joins PBS Biotech, Inc. as Vice President Manufacturing & Operations
Innovative Bioprocess Solutions
NEWS RELEASE, For Immediate Release
Randy Ray Joins PBS Biotech, Inc. as
Vice President Manufacturing & Operations
Camarillo, California, April 11, 2011–PBS Biotech, Inc., a developer of state of the art bioreactors used in the fast growing biotechnology market, announced today Randy Ray has joined the company as the Vice President of Manufacturing and Operations. Mr. Ray reports to President Dr. Brian Lee.
Mr. Ray is a highly experienced manufacturing, program management and project engineer with a broad background developing systems, high technology commercial and industrial products and components for a wide range of industries including defense, aerospace, automotive, media distribution and specialty materials.
Prior to joining PBS Biotech he was the national sales manager at Abrisa Technologies, which makes high quality fabricated glass components, optical thin film coatings and custom glass designs for industrial and government applications. Previously he was director of automotive programs at Kavlico Corporation where he headed major automotive programs for the Big 3 US automakers and European automobile manufacturers.
Mr. Ray earned his mechanical engineering degree at UC Santa Barbara and a master’s degree in mechanical engineering from Stanford.
About PBS Biotech
PBS Biotech, Inc. is a US corporation that manufactures fully scalable and easy to use single-use bioreactors for global biotechnology organizations. The company has patented innovative industrial designs and advanced software driven control systems that produce low shear, cell culture solutions improving operational flexibility and process efficiency, reducing operating costs and accelerating time to market for biotechnology customers. With headquarters in Camarillo, CA. the company is poised for rapid growth to support industry demand for single-use technologies.
Contact: James B. Schultz, VP – Sales & Marketing
+1 805-990-6177
PDF Version